CAS 179324-69-7
:Bortezomib
Descrizione:
Bortezomib è un inibitore del proteasoma utilizzato principalmente nel trattamento del mieloma multiplo e di alcuni tipi di linfoma. È un composto sintetico che appartiene alla classe dei derivati dell'acido borico. La formula chimica di Bortezomib è C19H25BoroN4O4 e presenta un atomo di boro che gioca un ruolo cruciale nel suo meccanismo d'azione, che implica l'inibizione del proteasoma, un complesso cellulare responsabile della degradazione delle proteine ubiquitinate. Questa inibizione porta all'accumulo di fattori pro-apoptotici e regolatori del ciclo cellulare, inducendo infine l'apoptosi nelle cellule tumorali. Bortezomib viene somministrato tramite iniezione endovenosa o sottocutanea ed è noto per i suoi effetti collaterali, che possono includere neuropatia periferica, problemi gastrointestinali e tossicità ematologiche. La sua farmacocinetica prevede un rapido assorbimento e distribuzione, con una emivita che consente schemi di dosaggio efficaci. In generale, Bortezomib rappresenta un significativo progresso nella terapia mirata contro il cancro, mostrando il potenziale delle piccole molecole nel trattamento delle neoplasie ematologiche.
Formula:C19H25BN4O4
InChI:InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
InChI key:InChIKey=GXJABQQUPOEUTA-RDJZCZTQSA-N
SMILES:[C@H](CC1=CC=CC=C1)(C(N[C@@H](CC(C)C)B(O)O)=O)NC(=O)C=2C=NC=CN2
Sinonimi:- B-[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid
- Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-
- Boronic acid, [(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-
- Boronic acid, [3-methyl-1-[[1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-, [S-(R*,S*)]-
- Bortezomib for research
- Bortizomib
- Brotezamide
- Dpba
- Ldp 341
- Mg 341
- Mln 341
- N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
- N-[(1S)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-D-phenylalaninamide
- NSC 681239
- PS 341 (pharmaceutical)
- Ps 314
- Ps 341
- Radiciol
- Velcade
- Vedi altri sinonimi
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
13 prodotti.
Bortezomib
CAS:Formula:C19H25BN4O4Purezza:>98.0%(HPLC)Colore e forma:White to Almost white powder to crystalPeso molecolare:384.24Bortezomib, 98%
CAS:<p>Bortezomib, 179324-69-7, is a peptidic boronic acid analog and antineoplastic agent which turns off cell signaling pathways through 26S proteasome inhibition. Learn more.</p>Formula:C19H25BN4O4Purezza:98%Colore e forma:Powder or crystals or crystalline powder, White to off-whitePeso molecolare:384.24Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-
CAS:Formula:C19H25BN4O4Purezza:98%Colore e forma:SolidPeso molecolare:384.2372Bortezomib
CAS:Formula:C19H25BN4O4Purezza:≥ 98.0%Colore e forma:White to off-white powder or solidPeso molecolare:384.24Bortezomib
CAS:<p>Bortezomib</p>Formula:C19H25BN4O4Purezza:98% (nmr) (Typical Value in Batch COA)Colore e forma: white solidPeso molecolare:384.24g/molRef: 4Z-B-4697
5mgPrezzo su richiesta10mgPrezzo su richiesta25mgPrezzo su richiesta50mgPrezzo su richiesta100mgPrezzo su richiestaBortezomib
CAS:<p>Bortezomib (LDP 341) is a 20S proteasome inhibitor (Ki=0.6 nM) that is reversible and selective.</p>Formula:C19H25BN4O4Purezza:97.79% - >99.99%Colore e forma:Yellow SolidPeso molecolare:384.24Bortezomib-D8 (Major)
CAS:Prodotto controllato<p>Applications Labelled Bortezomib, which the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells.d6-3%d7-10%d8-86%<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Nawrocki, S.T., et al: Cancer Research, 65, 11510 (2005)<br></p>Formula:C19H17D8BN4O4Colore e forma:Off-WhitePeso molecolare:392.29Bortezomib
CAS:Prodotto controllato<p>Stability Hygroscopic and Moisture Sensitive<br>Applications Bortezomib is the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. Targets the ubiquitin-proteasome pathway.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Nawrocki, S.T., et al: Cancer Research, 65, 11510 (2005); Drahl C.: Chem. and Eng. News, 87, 41 (2009);<br></p>Formula:C19H25BN4O4Colore e forma:White To Off-WhitePeso molecolare:384.24Bortezomib - Bio-X ™
CAS:<p>Bortezomib is a selective and reversible inhibitor of the multicatalytic 26S proteasome. The inhibition of protein breakdown affects several metabolic pathways and leads to cell death. The compound is effective in treating t-cell lymphomas and multiple myeloma because it prevents the binding of myeloma cells to bone marrow stroma and inhibits osteoclast differentiation.</p>Formula:C19H25BN4O4Purezza:Min. 95%Colore e forma:PowderPeso molecolare:384.24 g/molBortezomib
CAS:<p>Selective and reversible inhibitor of the multicatalytic 26S proteasome. The inhibition of protein breakdown affects several metabolic pathways and leads to cell death. The compound is effective in treating multiple myeloma because it prevents the binding of myeloma cells to bone marrow stroma and inhibits osteoclast differentiation.</p>Formula:C19H25BN4O4Purezza:Min. 95%Colore e forma:White PowderPeso molecolare:384.24 g/mol
![Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]…](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb%2FDA0026XG.jpg&w=3840&q=75)
